Literature DB >> 23023162

Pharmacological treatment of anxiety disorders: current treatments and future directions.

Frank J Farach1, Larry D Pruitt, Janie J Jun, Alissa B Jerud, Lori A Zoellner, Peter P Roy-Byrne.   

Abstract

Modern pharmacological treatments for anxiety disorders are safer and more tolerable than they were 30 years ago. Unfortunately, treatment efficacy and duration have not improved in most cases despite a greater understanding of the pathophysiology of anxiety. Moreover, innovative treatments have not reached the market despite billions of research dollars invested in drug development. In reviewing the literature on current treatments, we argue that evidence-based practice would benefit from better research on the causes of incomplete treatment response as well as the comparative efficacy of drug combinations and sequencing. We also survey two broad approaches to the development of innovative anxiety treatments:the continued development of drugs based on specific neuroreceptors and the pharmacological manipulation of fear-related memory. We highlight directions for future research, as neither of these approaches is ready for routine clinical use.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23023162      PMCID: PMC3539724          DOI: 10.1016/j.janxdis.2012.07.009

Source DB:  PubMed          Journal:  J Anxiety Disord        ISSN: 0887-6185


  143 in total

Review 1.  Memory--a century of consolidation.

Authors:  J L McGaugh
Journal:  Science       Date:  2000-01-14       Impact factor: 47.728

Review 2.  Effects of β-blocker selectivity on blood pressure variability and stroke: a systematic review.

Authors:  Alastair John Stewart Webb; Urs Fischer; Peter Malcolm Rothwell
Journal:  Neurology       Date:  2011-07-27       Impact factor: 9.910

3.  Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult.

Authors:  Cornelius Gross; Xiaoxi Zhuang; Kimberly Stark; Sylvie Ramboz; Ronald Oosting; Lynn Kirby; Luca Santarelli; Sheryl Beck; René Hen
Journal:  Nature       Date:  2002-03-28       Impact factor: 49.962

4.  Do antidepressants cause suicidality in children? A Bayesian meta-analysis.

Authors:  Eloise E Kaizar; Joel B Greenhouse; Howard Seltman; Kelly Kelleher
Journal:  Clin Trials       Date:  2006       Impact factor: 2.486

5.  Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication.

Authors:  Philip S Wang; Michael Lane; Mark Olfson; Harold A Pincus; Kenneth B Wells; Ronald C Kessler
Journal:  Arch Gen Psychiatry       Date:  2005-06

6.  D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial.

Authors:  Anja Siegmund; Fabian Golfels; Claudia Finck; Anna Halisch; Daniela Räth; Jens Plag; Andreas Ströhle
Journal:  J Psychiatr Res       Date:  2011-03-05       Impact factor: 4.791

7.  Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol.

Authors:  Paolo Fusar-Poli; Paul Allen; Sagnik Bhattacharyya; José A Crippa; Andrea Mechelli; Stefan Borgwardt; Rocio Martin-Santos; Marc L Seal; Colin O'Carrol; Zerrin Atakan; Antonio W Zuardi; Philip McGuire
Journal:  Int J Neuropsychopharmacol       Date:  2009-09-24       Impact factor: 5.176

8.  A controlled trial of flumazenil and gabapentin for initial treatment of methylamphetamine dependence.

Authors:  Harold C Urschel; Larry L Hanselka; Michael Baron
Journal:  J Psychopharmacol       Date:  2009-11-25       Impact factor: 4.153

9.  Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings.

Authors:  U D McCann; Z Szabo; U Scheffel; R F Dannals; G A Ricaurte
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

10.  A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder.

Authors:  Mark Pollack; Richard Mangano; Richard Entsuah; Evan Tzanis; Naomi M Simon; Ying Zhang
Journal:  Psychopharmacology (Berl)       Date:  2007-06-23       Impact factor: 4.530

View more
  25 in total

1.  Association between suicide death and concordance with benzodiazepine treatment guidelines for anxiety and sleep disorders.

Authors:  Jennifer M Boggs; Richard C Lindrooth; Catherine Battaglia; Arne Beck; Debra P Ritzwoller; Brian K Ahmedani; Rebecca C Rossom; Frances L Lynch; Christine Y Lu; Beth E Waitzfelder; Ashli A Owen-Smith; Gregory E Simon; Heather D Anderson
Journal:  Gen Hosp Psychiatry       Date:  2019-11-17       Impact factor: 3.238

2.  GABAA Receptor Density Is Not Altered by a Novel Herbal Anxiolytic Treatment.

Authors:  Ravid Doron; Avital Sever; Assaf Handelsman; Roni Toledano; Motty Franko; Yafit Hirshler; Alon Shamir; Or Burstein; Moshe Rehavi
Journal:  J Mol Neurosci       Date:  2018-05-08       Impact factor: 3.444

3.  In vivo and in vitro evaluations of intestinal gabapentin absorption: effect of dose and inhibitors on carrier-mediated transport.

Authors:  Malte Selch Larsen; Sidsel Frølund; Martha Kampp Nøhr; Carsten Uhd Nielsen; Mats Garmer; Mads Kreilgaard; René Holm
Journal:  Pharm Res       Date:  2014-09-03       Impact factor: 4.200

4.  Potential Role of Vitamin D for the Management of Depression and Anxiety.

Authors:  Gleicilaine A S Casseb; Manuella P Kaster; Ana Lúcia S Rodrigues
Journal:  CNS Drugs       Date:  2019-07       Impact factor: 5.749

Review 5.  Benefit-Risk Assessment of Psychotropic Drugs in Older Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Abebaw Mengistu Yohannes; Jeff W Jin; Mark E Kunik
Journal:  Drugs Aging       Date:  2022-04-19       Impact factor: 3.923

6.  Anxiolytic and antidepressants' effect of Crataegus pinnatifida (Shan Zha): biochemical mechanisms.

Authors:  Keren Nitzan; Dekel David; Motty Franko; Roni Toledano; Sharon Fidelman; Yaarit Simchon Tenenbaum; Maya Blonder; Shir Armoza-Eilat; Alon Shamir; Moshe Rehavi; Yair Ben-Chaim; Ravid Doron
Journal:  Transl Psychiatry       Date:  2022-05-19       Impact factor: 7.989

7.  First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist.

Authors:  Priska Kaufmann; Marion Ort; Georg Golor; Rüdiger Kornberger; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2020-03-06       Impact factor: 4.335

Review 8.  The role of oxidative stress in anxiety disorder: cause or consequence?

Authors:  Alessandra das Graças Fedoce; Frederico Ferreira; Robert G Bota; Vicent Bonet-Costa; Patrick Y Sun; Kelvin J A Davies
Journal:  Free Radic Res       Date:  2018-06-04

9.  A major role for common genetic variation in anxiety disorders.

Authors:  Gerome Breen; Thalia C Eley; Kirstin L Purves; Jonathan R I Coleman; Sandra M Meier; Christopher Rayner; Katrina A S Davis; Rosa Cheesman; Marie Bækvad-Hansen; Anders D Børglum; Shing Wan Cho; J Jürgen Deckert; Héléna A Gaspar; Jonas Bybjerg-Grauholm; John M Hettema; Matthew Hotopf; David Hougaard; Christopher Hübel; Carol Kan; Andrew M McIntosh; Ole Mors; Preben Bo Mortensen; Merete Nordentoft; Thomas Werge; Kristin K Nicodemus; Manuel Mattheisen
Journal:  Mol Psychiatry       Date:  2019-11-20       Impact factor: 15.992

10.  Critical Roles of Embryonic Born Dorsal Dentate Granule Neurons for Activity-Dependent Increases in BDNF, Adult Hippocampal Neurogenesis, and Antianxiety-like Behaviors.

Authors:  Dong Sun; Leena Milibari; Jin-Xiu Pan; Xiao Ren; Ling-Ling Yao; Yang Zhao; Chen Shen; Wen-Bing Chen; Fu-Lei Tang; Daehoon Lee; Jun-Shi Zhang; Lin Mei; Wen-Cheng Xiong
Journal:  Biol Psychiatry       Date:  2020-09-07       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.